Abstract
The rates of Grade 3 or greater acute esophagitis in patients treated with definitive radiotherapy for lung cancer have been less than 5%. However, the increasing use of concomitant chemoradiotherapy to improve tumor outcomes has been associated with rates of acute esophagitis greater than 15%. The use of intensity-modulated radiation therapy (IMRT) has allowed dose sparing of organs at risk, such as the esophagus, during the treatment planning process. Furthermore, respiratory gating is used to reduce the margin needed for target motion, resulting in smaller treatment volumes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
